Is Apnimed, Inc. (APMD) a Buy, Sell, or Hold?
NASDAQ : APMD
Apnimed, Inc. — News
$27 USD
-$0.88 (-3.16%)
- Volume
- 160.89K
- Average Volume
- 898.33K
- Market Capitalization
- $1.08B
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $29.15
- Year Low
- $16.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share. globenewswire.com - 2026-08-03 16:35:00 |
|
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States. reuters.com - 2026-07-27 08:16:43 |
|
Apnimed Seeks IPO For OSA Treatment Commercialization
Apnimed, Inc. is pursuing an IPO to fund regulatory approval and initial commercialization of its lead OSA drug, Oxnimbi (AD109). AD109 has shown strong efficacy in Phase 3 trials and an FDA decision is expected within a year, assuming no delays. APMD recently monetized its Shionogi JV interest, sharpening focus on regulatory and commercial execution for its sole product. seekingalpha.com - 2026-07-23 10:38:59 |
